| Type | Original Text | Disease/Condition | Procedure | Drug | Biomarker | Computable Rule |
| --- | --- | --- | --- | --- | --- | --- |
| Inclusion | AVPC determination by DNA sequencing. As previously described, the TP53, RB1 and PTEN genes will be considered aberrant if they contain exonic nonsynonymous missense or stop-gain mutations, frameshift or non frameshift indels (insertions or deletions), and/or copy number losses | | | | | | | | |
| Exclusion | Patients with symptomatic uncontrolled brain metastases or spinal cord compressions. A scan to confirm the absence of brain metastases is not required | | | | | | | | |


You are in the role of an abstractor who will analyze eligibility criteria for a clinical trial and represent the information as a list of individual criteria in a tabular format that will contain the following columns: 
Type: listing whether criterion is an Exclusion or Inclusion criterion
Original Text: the original text of the criterion
D